Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 4/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213923 | 0.92 | MMP13 (0.54) | PPARGMMP13RXFP1LMNAPOLB | |
| SCHEMBL6213121 | 0.91 | MMP13 (0.49) | PPARGPIK3CAMMP13RXFP1PARP1 | |
| SCHEMBL6212605 | 0.90 | PIK3CA (0.46) | PIK3CAMMP13RXFP1ROCK2PARP1 | |
| SCHEMBL6213639 | 0.90 | ALDH1A1 (0.52) | PIK3CAMMP13RXFP1ROCK2PARP1 | |
| SCHEMBL6213339 | 0.87 | PIK3CA (0.44) | PIK3CAMMP13RXFP1ROCK2NAMPT | |
| SCHEMBL6214403 | 0.86 | ESR1 (0.54) | PPARGRXFP1POLBMAPTTP53 | |
| SCHEMBL6212989 | 0.85 | MMP13 (0.54) | PPARGMMP13RXFP1LMNAPOLB | |
| SCHEMBL6212954 | 0.85 | MMP13 (0.60) | PPARGMMP13RXFP1LMNAPOLB | |
| SCHEMBL6214058 | 0.84 | MMP13 (0.54) | PPARGMMP13RXFP1ROCK2LMNA | |
| SCHEMBL6730033 | 0.83 | PARG (0.52) | PPARGPIK3CAMMP13ROCK2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362048-B1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | WARNER LAMBERT CO (US) | 2005-05-04 | — | — | EP | claimed |
| US-6849637-B2 | Triazolo compounds as MMP inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | claimed |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | ANDRIANJARA CHARLES (FR) | 2002-10-17 | — | — | US | claimed |
| US-6849637-B2 | Triazolo compounds as MMP inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | ANDRIANJARA CHARLES (FR) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | PPARG 1806/4885PIK3CA 2595/4885MMP13 1/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | PPARG 497/4885PIK3CA 1232/4885MMP13 1/4885 |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | MMP8, MMP13, MMP9 | PPARG 3314/4885PIK3CA 3926/4885MMP13 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.